The Institute of Cancer Research, London, is one of the world’s most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years. We provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today, The Institute of Cancer Research (ICR) leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment. Under the leadership of our Interim Chief Executive, Professor Paul Workman FMedSci, the ICR is ranked as the UK’s leading academic research centre. Together with our partner The Royal Marsden, we are rated in the top four cancer centres globally. The ICR is committed to attracting, developing and retaining the best minds in the world to join us in our mission – to make the discoveries that defeat cancer. The Cancer Research UK Cancer Therapeutics Unit, within the Division of Cancer Therapeutics, is a multidisciplinary 'bench to bedside' centre, comprising around 160 staff dedicated to the discovery and development of novel therapeutics for the treatment of cancer. The Cancer Therapeutics Unit’s exciting goal is to discover high quality drug candidates for validated biological targets and to progress these candidates to clinical trial. All the scientific disciplines are in place to make this possible, including medicinal chemistry, biology, drug metabolism and clinical specialists. This is an exciting and fast moving area of cancer research, and offers the opportunity to work within a multi-disciplinary environment using state-of-the-art techniques and equipment. A postdoctoral position is now available in our Hit Discovery and Structural Design Team led by Dr Rob van Montfort. The successful candidate will be involved in protein-ligand crystallography, fragment-based screening and structure-based drug design and will be responsible for crystallisation and structural analysis of protein-ligand complexes from one or more of the Unit’s drug discovery programmes. The successful candidate will also be part of the Division of Structural Biology, in which the crystallographers in Dr van Montfort’s team are embedded, and will have access to state of the art crystallisation facilities, in-house X-ray sources and excellent access to synchrotrons. The successful candidate will also interact closely with our biology, computational chemistry and medicinal chemistry teams, and will therefore be expected to work across both our sites in London (Chelsea and Sutton). Applicants must have a PhD in a biological or physical science, and experience in macromolecular crystallography (to include protein biochemistry, protein crystallisation and protein crystallography). Experience in molecular biology, structure-based drug design, and/or biophysics would be an advantage. Starting salary will be in the range £28,966 to £34,359 p.a. inclusive (based on previous experience). Appointment will be on a fixed term contract of 2 years in the first instance. Informal enquiries to [email protected]<mailto:[email protected]> or [email protected]<mailto:[email protected]>. Please DO NOT send your application to Dr van Montfort or Dr Westwood; applications must be submitted via the ICR web site at www.icr.ac.uk<http://www.icr.ac.uk>.
Dr. Rob van Montfort Team Leader Hit Discovery and Structural Design Sections of Cancer Therapeutics and Structural Biology The Institute of Cancer Research 15 Cotswold Road Sutton SM2 5NG UK Tel: +44-(0)20-8722-4364 (Sutton) +44-(0)20-7153-5142 (Chelsea) Email: [email protected]<mailto:[email protected]> The Institute of Cancer Research: Royal Cancer Hospital, a charitable Company Limited by Guarantee, Registered in England under Company No. 534147 with its Registered Office at 123 Old Brompton Road, London SW7 3RP. This e-mail message is confidential and for use by the addressee only. If the message is received by anyone other than the addressee, please return the message to the sender by replying to it and then delete the message from your computer and network.
